The Human Diabetes Proteome Project (HDPP): From network biology to targets for therapies and prevention

Translational Proteomics

Volumn 1, Issue 1, 2013, Pages 3-11

  Topf, F ^a,b   Schvartz, D ^a   Gaudet, P ^b   Priego Capote, F ^c   Zufferey, A ^a   Turck, N ^a   Binz, P A ^b   Fontana, P ^a,d   Wiederkehr, A ^e   Finamore, F ^a   Xenarios, I ^b   Goodlett, D ^f,g   Kussmann, M ^e,h,i   Bergsten, P ^j   Sanchez, J C ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e NESTLÉ RESEARCH CENTER   (Switzerland)

^f TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^g UNIVERSITY OF MARYLAND   (United States)

^h EPFL   (Switzerland)

ⁱ AARHUS UNIVERSITY   (Denmark)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

Beta Cell; Diabetes; Fatty acids; Glucose; Human proteome; Islet; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; CARBON 13; GLUCOSE; LIPID; REACTIVE OXYGEN METABOLITE; SUGAR;

ACETYLATION; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BIOINFORMATICS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; GLYCATION; HUMAN; HUMAN DIABETES PROTEOME PROJECT; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PRODUCING BETA CELL; INSULINOMA; ISOTOPE LABELING; LIPID BLOOD LEVEL; LIPOTOXICITY; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; TOXICITY; TRANSCRIPTOMICS;

EID: 84959373914     PISSN: 22129626     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trprot.2013.03.002     Document Type: Review

References (42)

1. Pavy F.W. The Croonian lectures on a new departure in diabetes: delivered before the Royal College of Physicians of London. British Medical Journal 1894, 1(1747):1349-1350.
2. IDF International Diabetes Federation Diabetes Atlas Update 2012 2012, Available from: http://www.idf.org/diabetesatlas/5e/Update2012.
3. Gaudet P. neXtProt: organizing protein knowledge in the context of human proteome projects. Journal of Proteomic Research 2013, 12(1):293-298.
4. HUPO. Human Proteome Project (HPP). Available from: . http://www.hupo.org/research/hpp/.
5. Paik Y.-K. The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nature Biotechnology 2012, 30(3):221-223.
6. Aebersold R. The Biology/Disease-driven Human Proteome Project (B/D-HPP): enabling protein research for the life sciences community. Journal of Proteomic Research 2013, 12(1):23-27.
7. Butler A.E. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102-110.
8. Jensen C.C. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002, 51(7):2170-2178.
9. Lin J.M. Pulsatile insulin release from islets isolated from three subjects with type 2 diabetes. Diabetes 2002, 51(4):988-993.
10. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. American Journal of Medicine 2010, 123(3 Suppl):S3-S11.
11. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocrine Reviews 2008, 29(3):351-366.
12. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995, 44(8):863-870.
13. Prentki M. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. Journal of Biological Chemistry 1992, 267(9):5802-5810.
14. Sargsyan E., Bergsten P. Lipotoxicity is glucose-dependent in INS-1E cells but not in human islets and MIN6 cells. Lipids in Health and Disease 2011, 10:115.
15. Wright E., Scism-Bacon J.L., Glass L.C. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. International Journal of Clinical Practice 2006, 60(3):308-314.
16. Magrane M., Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011, 2011:bar009.
17. Bairoch A. Swiss-Prot: juggling between evolution and stability. Briefings in Bioinformatics 2004, 5(1):39-55.
18. Uhlen M. Towards a knowledge-based Human Protein Atlas. Nature Biotechnology 2010, 28(12):1248-1250.
19. Hermjakob H., Apweiler R. The Proteomics Identifications Database (PRIDE) and the ProteomExchange Consortium: making proteomics data accessible. Expert Review of Proteomics 2006, 3(1):1-3.
20. Desiere F. The PeptideAtlas project. Nucleic Acids Research 2006, 34(Database issue):D655-D658.
21. Huhmer A.F. The chromosome-centric human proteome project: a call to action. Journal of Proteomic Research 2013, 12(1):28-32.
22. Orchard S. Ten years of standardizing proteomic data: a report on the HUPO-PSI Spring Workshop: April 12-14th, 2012, San Diego, USA. Proteomics 2012, 12(18):2767-2772.
23. Drupal. Available from: . https://drupal.org/.
24. Asfari M. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992, 130(1):167-178.
25. Coute Y. Early activation of the fatty acid metabolism pathway by chronic high glucose exposure in rat insulin secretory beta-cells. Proteomics 2010, 10(1):59-71.
26. Schvartz D. Modulation of neuronal pentraxin 1 expression in rat pancreatic beta-cells submitted to chronic glucotoxic stress. Molecular & Cellular Proteomics 2012, 11(8):244-254.
27. 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Molecular & Cellular Proteomics 2010, 9(3):579-592.
28. Priego-Capote F. Human hemolysate glycated proteome. Analytical Chemistry 2011, 83(14):5673-5680.
29. IASO. International Association for the Study of Obesity: world map of obesity. Available from: . http://www.iaso.org/resources/world-map-obesity/.
30. Cox J. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nature Protocols 2009, 4(5):698-705.
31. Ashcroft F.M., Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell 2012, 148(6):1160-1171.
32. Wiederkehr A., Wollheim C.B. Mitochondrial signals drive insulin secretion in the pancreatic beta-cell. Molecular & Cellular Endocrinology 2012, 353(1-2):128-137.
33. Anello M. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 2005, 48(2):282-289.
34. Davi G., Patrono C. Platelet activation and atherothrombosis. New England Journal of Medicine 2007, 357(24):2482-2494.
35. Patrono C., Rocca B. Aspirin, 110 years later. Journal of Thrombosis and Haemostasis 2009, 7(Suppl 1):258-261.
36. Reny J.L. Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management. Cardiovascular Therapeutics 2012, 30(1):e41-e50.
37. Frelinger A.L. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009, 120(25):2586-2596.
38. Fontana P. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. Journal of Thrombosis and Haemostasis 2010, 8(12):2614-2623.
39. Rocca B. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis 2012, 10(7):1220-1230.
40. Angiolillo D.J., Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Practice & Research: Clinical Endocrinology & Metabolism 2009, 23(3):375-388.
41. Cimminiello C. Is aspirin effective in diabetic patients? No. Journal of Thrombosis and Haemostasis 2005, 3(12):2615-2616.
42. Bastian F. Bgee: integrating and comparing heterogeneous transcriptome data among species. Data integration in the life sciences 2008, 124-131. Springer, Berlin/Heidelberg. A. Bairoch, S. Cohen-Boulakia, C. Froidevaux (Eds.).